Treatment of obese diabetics

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 459-464

  Svačina, Štěpán ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; ANTIOBESITY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; LONG ACTING INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; TETRAHYDROLIPSTATIN; ANTIDIABETIC AGENT;

ARTICLE; BARIATRIC SURGERY; BODY WEIGHT DISORDER; COGNITIVE THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSURIA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LOW CALORY DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PATIENT EDUCATION; PHYSICAL ACTIVITY; WEIGHT GAIN; WEIGHT REDUCTION; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; WEIGHT LOSS;

MLCS; MLOWN;

EID: 84874549707     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_32     Document Type: Article

References (26)

1. Skrha J. In the name of Czech Diabetes Society committee: Diabetes mellitus-epidemiological study in Czech republic. DMEV 2005; 8:5-12.
2. Byrne Ch, Wild SH, ed. The Metabolic Syndrome, 2nd ed. Chichester:Wiley, 2011.
3. Ganz M, ed. Prevention of Type 2 Diabetes. Chichester: Wiley, 2005.
4. Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30(3):753-759.
5. Sjöström CD, Lissner L, Wedel H et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7(5):477-484.
6. Lean ME, Powrie JK, Anderson AS et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7(3):228-233.
7. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-1589.
8. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122(3):248-256.
9. 2: an integrative review of early studies. Obes Surg 2010; 20(6):776-790.
10. Regensteiner JG, Reusch JEB. Stewart K et al. Diabetes and Exercise. New York: Humana Press, 2009.
11. Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007; 8(11): 1733-1742.
12. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155-161.
13. Smith SR, Weissman NJ, Anderson CM et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363(3):245-256.
14. Goldberg RB, Temprosa M, Haffner S et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009; 32(4):726-732.
15. Martin S, Kolb H, Beuth J et al. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003;46(12):1611-1617.
16. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28(5): 1107-1112.
17. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9(1):31-8.
18. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32(4):650-657.
19. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13(1):7-18.
20. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24(1):275-286.
21. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374(9701): 1606-1616.
22. Bhushan R, Elkind-Hirsch KE, Bhushan M et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract 2008; 14(8):993-999.
23. Shyangdan DS, Royle PL, Clar C et al. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010; 10:20.e-publikace.
24. Ratner RE, Rosenstock J, Boka G et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010; 27(9): 1024-1032.
25. Christensen M, Knop FK, Holst JJ et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12(8):503-513.
26. Taylor K et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011; 11(1):9.